<DOC>
	<DOCNO>NCT00635882</DOCNO>
	<brief_summary>This 2-week double-blind , placebo-controlled , parallel group study compare anti-inflammatory effect low , medium , high dose mometasone furoate/formoterol fumarate ( MF/F ) meter dose inhaler ( MDI ) formulation medium dose mometasone furoate ( MF ) dry powder inhaler ( DPI ) MDI formulation adult adolescent persistent allergic asthma .</brief_summary>
	<brief_title>Asthma Study Comparing Anti-Inflammatory Effects 3 Doses Mometasone Furoate/Formoterol Fumarate Medium Dose Mometasone Furoate ( Study P05122 AM1 ) ( COMPLETED )</brief_title>
	<detailed_description>This 2-week double-blind , placebo-controlled , parallel group study compare anti-inflammatory effect low , medium , high dose mometasone furoate/formoterol fumarate MDI formulation medium dose mometasone furoate ( MF ) DPI MDI formulation adult adolescent persistent allergic asthma . An open-label run period follow double-blind treatment period . A total 90 subject ( 15 per treatment ) enrol ensure 12 subject per treatment Day 14 evaluation , account 20 % drop-out rate . A sample size 12 subject per treatment require detect treatment difference 28 % percent change eNO Day 14 , assume pool standard deviation 20 % power 90 % . These estimate base examination eNO level asthmatic v healthy subject article write S.A. Kharitonov et . al , 2003 . Subjects randomize one six treatment group ( MF/F MDI 100/10 mcg BID , MF/F MDI 200/10 mcg BID , MF/F MDI 400/10 mcg BID , MF DPI 200 mcg BID , MF MDI 200 mcg BID , Placebo MDI BID ) accord Schering-Plough Research Institute ( SPRI ) computer-generated randomization schedule . Randomization perform appropriately size block use random number generate statistical analysis software ( SAS ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>To document asthma diagnosis , historical reversibility define increase absolute force expiratory volume ( liter ) 1 second ( FEV1 ) &gt; = 12 % &gt; = 200 mL must perform within 12 month Screening . For subject without historical reversibility , one follow method use Screening Visit time Baseline Visit : Demonstration increase absolute FEV1 least 12 % volume increase least 200 mL within 1520 minute administration 4 inhalation albuterol/salbutamol ( total dose 360 400 mcg ) nebulized shortacting beta agonist ( SABA ) ( 2.5 mg ) , confirm standard office practice , OR Demonstration peak expiratory flow ( PEF ) variability 20 % express percentage mean high low morning prebronchodilator PEF least 1 week , OR Demonstration diurnal variation PEF 20 % base difference prebronchodilator ( take albuterol/salbutamol ) morning value postbronchodilator value ( take albuterol/salbutamol ) evening , express percentage mean daily PEF value day openlabel Runin Period . { The calculation formula : Diurnal PEF Variation = Absolute [ ( high 3 reading , PM Postbronchodilator ( BD ) PEF prior even ) ( high 3 reading , AM PreBD morning value ) ] / [ ( high PM PostBD + high AM PreBD ) /2 ] * 100 } At Screening Baseline Visits , subject must persistent allergic asthma FEV1 &gt; 65 % predict . A subject must allergic least one common allergen ( grass , tree , weed , house dust mite , mold , dog cat ) demonstrate clinical symptom expose allergen ( ) , skin prick test radioallergosorbent ( RAST ) class &gt; 1 ( exclude modify RAST procedure [ mRAST ] ) within 2 year inclusion study . If , base upon medical judgment investigator , inherent harm change subject 's current asthma therapy , subject and/or parent/guardian ) must agree discontinue prescribe inhaled corticosteroid ( ICS ) , anticholinergic , leukotriene receptor inhibitor , longacting beta2 agonist Screening Visit per require washout , transfer treatment SABA relief 2 week Baseline/Randomization Visit . Clinical laboratory test ( complete blood count , blood chemistry , urinalysis ) conduct Screening Visit must within normal limit clinically acceptable investigator . An electrocardiogram ( ECG ) perform Screening Visit within 30 day prior Screening Visit must clinically acceptable investigator QTc interval &lt; 440 millisecond male &lt; 450 msec female . At Screening time prior Baseline , subject must eNO level &gt; 30 part per billion ( ppb ) flow rate 50 mL/second . At Screening time Baseline , subject must sputum eosinophil count &gt; 3 % total cell count . Willingness give write informed consent ability adhere dose visit schedule . A subject 12 17 year age must also provide write assent . A nonpregnant female subject childbearing potential ( negative serum pregnancy test Screening ) must use medically acceptable , adequate form birth control . If currently sexually active must agree use doublebarrier method become sexually active study . Use systemic glucocorticosteroids within 3 month Screening . Upper low respiratory tract infection within 4 week Screening . Decrease absolute FEV1 &gt; 20 % Screening Baseline Visits . Requirement &gt; 8 inhalation per day SABA MDI , 2 nebulized treatment 2.5 mg SABA , 2 consecutive day Screening Baseline Visits . A decrease AM PM PEF Runin Period stability limit 2 consecutive day Baseline . At Visit 1 , Runin Period stability limit PEF establish base subject 's personal best . If subject historical personal best , historical PEF measurement PEF predict base subject 's sex , age , height . PEF value multiply 0.70 determine stability limit . A clinical asthma exacerbation define clinical deterioration asthma result emergency treatment , hospitalization asthma , treatment additional , exclude asthma medication ( include oral systemic corticosteroid allow SABA ) , per investigator , Screening Baseline Visits . Inability induce sputum 1 2 try .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>mometasone</keyword>
	<keyword>formoterol</keyword>
</DOC>